Cargando…
QuantiFERON-TB Gold In-Tube test conversions and reversions among tuberculosis patients and their household contacts in Addis Ababa: a one year follow-up study
BACKGROUND: QuantiFERON-TB Gold In-Tube® (QFT-GIT) test is used for the diagnosis of latent tuberculosis (TB) infection. Besides, QFT-GIT test could allow tracking changes in immune response among TB patients and their contacts. In high TB burden settings, reports on QFT-GIT conversions and reversio...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264256/ https://www.ncbi.nlm.nih.gov/pubmed/25466365 http://dx.doi.org/10.1186/s12879-014-0654-5 |
_version_ | 1782348703860785152 |
---|---|
author | Belay, Mulugeta Legesse, Mengistu Dagne, Daniel Mihret, Adane Bekele, Yonas Medhin, Girmay Bjune, Gunnar Abebe, Fekadu |
author_facet | Belay, Mulugeta Legesse, Mengistu Dagne, Daniel Mihret, Adane Bekele, Yonas Medhin, Girmay Bjune, Gunnar Abebe, Fekadu |
author_sort | Belay, Mulugeta |
collection | PubMed |
description | BACKGROUND: QuantiFERON-TB Gold In-Tube® (QFT-GIT) test is used for the diagnosis of latent tuberculosis (TB) infection. Besides, QFT-GIT test could allow tracking changes in immune response among TB patients and their contacts. In high TB burden settings, reports on QFT-GIT conversions and reversions among TB patients and their contacts are limited. As part of a major project to study immune responses to TB infection, we investigated QFT-GIT test conversions and reversions among smear positive pulmonary TB patients and their household contacts over 12 months. METHODS: We followed a total of 107 HIV negative participants (33 patients and 74 contacts) in Addis Ababa. We did QFT-GIT test at baseline and 12 months later according to the manufacturer’s instructions. RESULTS: At baseline, 25/33 (75.8%) of the patients and 50/74 (67.6%) of the contacts were QFT-GIT positive. At 12 months, 2 more patients (1 test negative and 1 indeterminate) became test positive. Besides, 11/24 (45.8%) test negative contacts became positive. Only one patient and one contact who were test positive at baseline became test negative 12 months later. At 12 months, the proportions of QFT-GIT test positives for patients and contacts were, therefore, 78.8% and 81.1%, respectively. Among contacts, the proportion of QFT-GIT test positives at 12 months was significantly higher compared to the corresponding proportion at baseline (McNemar, p = 0.006); similarly, the median IFN-γ response significantly increased at 12 months compared with the baseline level (Wilcoxon matched-pairs signed rank test, p = 0.01). Patients, however, had comparable median IFN-γ levels at baseline and 12 months later (p = 0.56). CONCLUSION: Nearly half of QFT-GIT negative household contacts at baseline became positive at 12 months. This suggests that repeated screening of QFT-GIT negative contacts may be needed for epidemiological studies and interventions of latent TB in an endemic setting. A large longitudinal study may be needed to confirm our observations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-014-0654-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4264256 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42642562014-12-13 QuantiFERON-TB Gold In-Tube test conversions and reversions among tuberculosis patients and their household contacts in Addis Ababa: a one year follow-up study Belay, Mulugeta Legesse, Mengistu Dagne, Daniel Mihret, Adane Bekele, Yonas Medhin, Girmay Bjune, Gunnar Abebe, Fekadu BMC Infect Dis Research Article BACKGROUND: QuantiFERON-TB Gold In-Tube® (QFT-GIT) test is used for the diagnosis of latent tuberculosis (TB) infection. Besides, QFT-GIT test could allow tracking changes in immune response among TB patients and their contacts. In high TB burden settings, reports on QFT-GIT conversions and reversions among TB patients and their contacts are limited. As part of a major project to study immune responses to TB infection, we investigated QFT-GIT test conversions and reversions among smear positive pulmonary TB patients and their household contacts over 12 months. METHODS: We followed a total of 107 HIV negative participants (33 patients and 74 contacts) in Addis Ababa. We did QFT-GIT test at baseline and 12 months later according to the manufacturer’s instructions. RESULTS: At baseline, 25/33 (75.8%) of the patients and 50/74 (67.6%) of the contacts were QFT-GIT positive. At 12 months, 2 more patients (1 test negative and 1 indeterminate) became test positive. Besides, 11/24 (45.8%) test negative contacts became positive. Only one patient and one contact who were test positive at baseline became test negative 12 months later. At 12 months, the proportions of QFT-GIT test positives for patients and contacts were, therefore, 78.8% and 81.1%, respectively. Among contacts, the proportion of QFT-GIT test positives at 12 months was significantly higher compared to the corresponding proportion at baseline (McNemar, p = 0.006); similarly, the median IFN-γ response significantly increased at 12 months compared with the baseline level (Wilcoxon matched-pairs signed rank test, p = 0.01). Patients, however, had comparable median IFN-γ levels at baseline and 12 months later (p = 0.56). CONCLUSION: Nearly half of QFT-GIT negative household contacts at baseline became positive at 12 months. This suggests that repeated screening of QFT-GIT negative contacts may be needed for epidemiological studies and interventions of latent TB in an endemic setting. A large longitudinal study may be needed to confirm our observations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-014-0654-5) contains supplementary material, which is available to authorized users. BioMed Central 2014-12-03 /pmc/articles/PMC4264256/ /pubmed/25466365 http://dx.doi.org/10.1186/s12879-014-0654-5 Text en © Belay et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Belay, Mulugeta Legesse, Mengistu Dagne, Daniel Mihret, Adane Bekele, Yonas Medhin, Girmay Bjune, Gunnar Abebe, Fekadu QuantiFERON-TB Gold In-Tube test conversions and reversions among tuberculosis patients and their household contacts in Addis Ababa: a one year follow-up study |
title | QuantiFERON-TB Gold In-Tube test conversions and reversions among tuberculosis patients and their household contacts in Addis Ababa: a one year follow-up study |
title_full | QuantiFERON-TB Gold In-Tube test conversions and reversions among tuberculosis patients and their household contacts in Addis Ababa: a one year follow-up study |
title_fullStr | QuantiFERON-TB Gold In-Tube test conversions and reversions among tuberculosis patients and their household contacts in Addis Ababa: a one year follow-up study |
title_full_unstemmed | QuantiFERON-TB Gold In-Tube test conversions and reversions among tuberculosis patients and their household contacts in Addis Ababa: a one year follow-up study |
title_short | QuantiFERON-TB Gold In-Tube test conversions and reversions among tuberculosis patients and their household contacts in Addis Ababa: a one year follow-up study |
title_sort | quantiferon-tb gold in-tube test conversions and reversions among tuberculosis patients and their household contacts in addis ababa: a one year follow-up study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264256/ https://www.ncbi.nlm.nih.gov/pubmed/25466365 http://dx.doi.org/10.1186/s12879-014-0654-5 |
work_keys_str_mv | AT belaymulugeta quantiferontbgoldintubetestconversionsandreversionsamongtuberculosispatientsandtheirhouseholdcontactsinaddisababaaoneyearfollowupstudy AT legessemengistu quantiferontbgoldintubetestconversionsandreversionsamongtuberculosispatientsandtheirhouseholdcontactsinaddisababaaoneyearfollowupstudy AT dagnedaniel quantiferontbgoldintubetestconversionsandreversionsamongtuberculosispatientsandtheirhouseholdcontactsinaddisababaaoneyearfollowupstudy AT mihretadane quantiferontbgoldintubetestconversionsandreversionsamongtuberculosispatientsandtheirhouseholdcontactsinaddisababaaoneyearfollowupstudy AT bekeleyonas quantiferontbgoldintubetestconversionsandreversionsamongtuberculosispatientsandtheirhouseholdcontactsinaddisababaaoneyearfollowupstudy AT medhingirmay quantiferontbgoldintubetestconversionsandreversionsamongtuberculosispatientsandtheirhouseholdcontactsinaddisababaaoneyearfollowupstudy AT bjunegunnar quantiferontbgoldintubetestconversionsandreversionsamongtuberculosispatientsandtheirhouseholdcontactsinaddisababaaoneyearfollowupstudy AT abebefekadu quantiferontbgoldintubetestconversionsandreversionsamongtuberculosispatientsandtheirhouseholdcontactsinaddisababaaoneyearfollowupstudy |